

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 July 2023 (06.07.2023)



(10) International Publication Number
WO 2023/126823 A1

- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/IB2022/062798
- (22) **International Filing Date:**
27 December 2022 (27.12.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/294,368 28 December 2021 (28.12.2021) US
- (71) **Applicants:** **ASTRAZENECA UK LIMITED** [GB/GB];
1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge CB2 0AA (GB). **DAIICHI SANKYO COM-
PANY, LIMITED** [JP/JP]; 3-5-1, Nihonbashi Honcho,
Chuo-ku, Tokyo 103-8426 (JP).
- (72) **Inventors:** **SUNG, Matthew Simon**; c/o AstraZeneca
Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437,
Wilmington, Delaware 19850-5437 (US). **LAU, Alan Yin
Kai**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave-
nue, Cambridge Biomedical Campus, Cambridge CB2
0AA (GB). **WALLEZ, Yann**; c/o AstraZeneca UK
Limited, 1 Francis Crick Avenue, Cambridge Biomed-
ical Campus, Cambridge CB2 0AA (GB). **METTETAL
II, Jerome Thomas**; c/o AstraZeneca Pharmaceuticals
LP, 1800 Concord Pike, P.O. Box 15437, Wilmington,
Delaware 19850-5437 (US). **PROIA, Theresa Angela**; c/
o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike,
P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).
RANDLE, Suzanne Jane; c/o AstraZeneca UK Limited,
1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge CB2 0AA (GB). **ANDERTON, Mark John**; c/

o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cam-
bridge Biomedical Campus, Cambridge CB2 0AA (GB).

(74) **Agent:** **FAIRBAIRN, Angus**; Marks & Clerk LLP, 15 Fet-
ter Lane, London EC4A 1BW (GB).


(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR



(57) **Abstract:** A pharmaceutical product for administration of an anti TROP2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-TROP2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an anti-TROP2 antibody) is conjugated to an anti-TROP2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the anti-TROP2 antibody-drug conjugate and the ATR inhibitor are administered in combination to a subject : Formula (I).



WO 2023/126823 A1